PT  - JOURNAL ARTICLE
AU  - Hatoum, Alexander S.
AU  - Johnson, Emma C.
AU  - Polimanti, Renato
AU  - Zhou, Hang
AU  - Walters, Raymond
AU  - ,
AU  - Gelernter, Joel
AU  - Edenberg, Howard J.
AU  - Bogdan, Ryan
AU  - Agrawal, Arpana
TI  - The Addiction Genetic Factor <em>a</em><sub><em>(g)</em></sub>: A Unitary Genetic Vulnerability Characterizes Substance Use Disorders and Their Associations with Common Correlates
AID  - 10.1101/2021.01.26.21250498
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.26.21250498
4099  - http://medrxiv.org/content/early/2021/01/28/2021.01.26.21250498.short
4100  - http://medrxiv.org/content/early/2021/01/28/2021.01.26.21250498.full
AB  - Background Substance use disorders (SUDs) commonly co-occur with one another and with other psychiatric disorders. They share common features including high impulsivity, negative affect, and lower executive function. We estimate the shared genetic architecture across distinct SUDs, its independence from genetic liability to substance use, and its relation to genetic liability to impulsivity, negative affect, and executive function as well as non-substance psychopathology.Methods We tested whether a common genetic factor undergirds liability to problematic alcohol use (PAU), problematic tobacco use (PTU), cannabis use disorder (CUD), and opioid use disorder (OUD) by applying Genomic structural equation modelling to genome-wide association study statistics (Total N = 1,019,521; substance specific Ns range: 82,707-435,563 of European ancestry), while adjusting for the genetics of substance use (Ns = 184,765-632,802). We tested whether shared liability across SUDs is associated with behavioral constructs (risk taking, executive function, neuroticism; Ns = 328,339-427,037) and non-substance use psychopathology (mood/psychotic, compulsive, and early neurodevelopmental disorders).Results Shared genetic liability to PAU, PTU, CUD, and OUD was characterized by a unidimensional addiction factor (termed a(g)), independent of substance use. OUD and CUD demonstrated the largest loadings. a(g) was associated with risk taking, neuroticism, executive function, and non-substance psychopathology, but retained specific variance (standardized residual= .579).Interpretation A common genetic addictions factor partly explains susceptibility for alcohol, tobacco, cannabis and opioid use disorder. a(g) has unique pathways that are not shared with substance use or non-substance psychopathology, suggesting that addiction is not the linear combination of substance use and psychopathology.Competing Interest StatementJG is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists,” filed January 24, 2018.Funding StatementThis research was supported by MH109532 (AA, JG, HJE, ECJ) and T32DA007261 (ASH). AA acknowledges K02DA32573. ECJ was supported by F32AA027435. RP acknowledges R21DA047527. RB acknowledges R21-AA027827. The Substance Use Disorders Working Group of the Psychiatric Genomics Consortium (PGC-SUD) is supported by funds from NIDA and NIMH to MH109532. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB expedited review was given by the Washington University in St. Louis IRB. All data used in this study were made publicly available by the cited consortia/research entities. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are made publicly available through their respective consortiums.